Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;31(2):e16049.
doi: 10.1111/ene.16049. Epub 2023 Sep 11.

Anti-amyloid antibody treatments for Alzheimer's disease

Affiliations
Review

Anti-amyloid antibody treatments for Alzheimer's disease

Robert Perneczky et al. Eur J Neurol. 2024 Feb.

Abstract

Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid-β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association. After numerous unsuccessful endeavors to create a disease-modifying therapy for Alzheimer's disease, substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid-β is finally emerging. The latest trials not only achieved their primary objective of slowing the progression of the disease over several months but also demonstrated positive secondary clinical outcomes and a decrease in amyloid-β levels as observed through positron emission tomography scans. Taken as a whole, these findings mark a significant breakthrough by substantiating that reducing amyloid-β yields tangible clinical benefits, beyond mere changes in biomarkers. Concurrently, the regular utilization of the new generation of drugs will determine whether statistical efficacy translates into clinically meaningful improvements. This may well signify the dawning of a new era in the development of drugs for Alzheimer's disease.

Keywords: anti-amyloid immunisation; fluid and imaging biomarkers; mild cognitive impairment and dementia; monoclonal antibodies; treatment of cognitive decline.

PubMed Disclaimer

Conflict of interest statement

R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen‐Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk; and was principal investigator on the aducanumab phase 3 trials. P.F. has received research support/honoraria for lectures or advisory activities from Boehringer‐Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter.

Figures

FIGURE 1
FIGURE 1
Schematic illustration of various antibodies targeting different amyloid‐β aggregation states (Source: developer data; reprinted with permission from reference 29).

References

    1. 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17:327‐406. - PubMed
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353‐356. - PubMed
    1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging−Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263‐269. - PMC - PubMed
    1. Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535‐562. - PMC - PubMed
    1. Ashton NJ, Janelidze S, Mattsson‐Carlgren N, et al. Differential roles of Abeta42/40, p‐tau231 and p‐tau217 for Alzheimer's trial selection and disease monitoring. Nat Med. 2022;28:2555‐2562. - PMC - PubMed

MeSH terms